299 related articles for article (PubMed ID: 30697932)
1. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
[TBL] [Abstract][Full Text] [Related]
2. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
3. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
[TBL] [Abstract][Full Text] [Related]
4. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
[TBL] [Abstract][Full Text] [Related]
5. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed,
Petersen ALOA; Campos TA; Dantas DADS; Rebouças JS; da Silva JC; de Menezes JPB; Formiga FR; de Melo JV; Machado G; Veras PST
Front Cell Infect Microbiol; 2018; 8():303. PubMed ID: 30214897
[TBL] [Abstract][Full Text] [Related]
7. 17 AAG for HSP90 inhibition in cancer--from bench to bedside.
Usmani SZ; Bona R; Li Z
Curr Mol Med; 2009 Jun; 9(5):654-64. PubMed ID: 19601813
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
9. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
[TBL] [Abstract][Full Text] [Related]
10. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
11. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Miyata Y
Curr Pharm Des; 2005; 11(9):1131-8. PubMed ID: 15853661
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
[TBL] [Abstract][Full Text] [Related]
14. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the HSP90 molecular chaperone: current status.
Sharp S; Workman P
Adv Cancer Res; 2006; 95():323-48. PubMed ID: 16860662
[TBL] [Abstract][Full Text] [Related]
16. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
17. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
[TBL] [Abstract][Full Text] [Related]
18. VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer.
Onyüksel H; Mohanty PS; Rubinstein I
Int J Pharm; 2009 Jan; 365(1-2):157-61. PubMed ID: 18793708
[TBL] [Abstract][Full Text] [Related]
19. The Hsp90 chaperone complex as a novel target for cancer therapy.
Goetz MP; Toft DO; Ames MM; Erlichman C
Ann Oncol; 2003 Aug; 14(8):1169-76. PubMed ID: 12881371
[TBL] [Abstract][Full Text] [Related]
20. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
